Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 16

recruiting
3 968
countries
28
conditions
2 103

439 trials match your criteria

Prostate cancer

Recruiting

Study on the Use of [18F]PSMA-1007 PET/CT Imaging for Detecting Prostate Cancer in Patients with Newly Diagnosed High-Risk or Very-High-Risk Conditions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-[[(1S)-1-Carboxy-5-[[(2S)-2-[[4-[[[(2S)-4-Carboxy-2-[[(2S)-4-Carboxy-2-[(6-(18F)Fluoranylpyridine-3-Carbonyl)Amino]Butanoyl]Amino]Butanoyl]Amino]Methyl]Benzoyl]Amino]-3-Naphthalen-2-Ylpropanoyl]Amino]Pentyl]Carbamoylamino]Pentanedioic Acid

Gastrooesophageal cancer+1

Recruiting

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Colorectal adenocarcinoma

Recruiting

Study of Pre-Operative Treatments with Sotorasib and Drug Combination for Patients with Resectable Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Prostate cancer metastatic

Recruiting

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Biliary neoplasm

Recruiting

Study on Cisplatin, Gemcitabine, and Paclitaxel Albumin-Bound for Patients with Resectable Biliary Tract Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Neuroendocrine tumour+1

Recruiting

Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Leiomyosarcoma+1

Recruiting

Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belumosudil Mesilate

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Endometrial cancer+2

Recruiting

Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.